Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2025

SELL
$41.33 - $74.26 $404,496 - $726,782
-9,787 Closed
0 $0
Q1 2024

Jul 31, 2025

SELL
$56.27 - $73.77 $13,054 - $17,114
-232 Reduced 2.32%
9,787 $675,000
Q4 2023

Jul 31, 2025

SELL
$59.06 - $75.72 $59,060 - $75,720
-1,000 Reduced 9.08%
10,019 $741,000
Q3 2023

Jul 31, 2025

SELL
$65.94 - $99.04 $3.77 Million - $5.66 Million
-57,102 Reduced 83.82%
11,019 $751,000
Q2 2023

Jul 31, 2025

SELL
$62.68 - $95.05 $23,003 - $34,883
-367 Reduced 0.54%
68,121 $6.4 Million
Q1 2023

Jul 31, 2025

BUY
$47.19 - $70.77 $990 - $1,486
21 Added 0.03%
68,488 $4.64 Million
Q4 2022

Feb 06, 2023

BUY
$30.35 - $53.15 $36,359 - $63,673
1,198 Added 1.78%
68,467 $3.39 Million
Q3 2022

Nov 01, 2022

BUY
$31.97 - $49.37 $4,859 - $7,504
152 Added 0.23%
67,269 $2.19 Million
Q2 2022

Jul 18, 2022

SELL
$35.61 - $76.23 $890 - $1,905
-25 Reduced 0.04%
67,117 $2.64 Million
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $95,146 - $136,438
-1,653 Reduced 2.4%
67,142 $4.7 Million
Q4 2021

Feb 08, 2022

BUY
$72.5 - $100.68 $3.51 Million - $4.87 Million
48,376 Added 236.92%
68,795 $5.35 Million
Q2 2021

Aug 03, 2021

BUY
$93.66 - $139.27 $58,443 - $86,904
624 Added 3.15%
20,419 $2.54 Million
Q1 2021

May 12, 2021

SELL
$116.57 - $155.01 $2.86 Million - $3.8 Million
-24,493 Reduced 55.3%
19,795 $2.61 Million
Q4 2020

Feb 16, 2021

BUY
$99.61 - $142.12 $2.2 Million - $3.14 Million
22,114 Added 99.73%
44,288 $5.87 Million
Q3 2020

Dec 03, 2020

BUY
$72.92 - $102.01 $1.62 Million - $2.26 Million
22,174 New
22,174 $2.26 Million
Q3 2019

Nov 14, 2019

SELL
$90.37 - $122.49 $16,085 - $21,803
-178 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$89.51 - $118.04 $15,932 - $21,011
178 New
178 $21,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $11.9B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Brinker Capital Investments, LLC Portfolio

Follow Brinker Capital Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.